{"id":"glisoxepide","rwe":[{"pmid":"39298002","year":"2024","title":"Deciphering the role of FOXP4 in long COVID: exploring genetic associations, evolutionary conservation, and drug identification through bioinformatics analysis.","finding":"","journal":"Functional & integrative genomics","studyType":"Clinical Study"},{"pmid":"37813637","year":"2023","title":"M Protein from Dengue virus oligomerizes to pentameric channel protein: in silico analysis study.","finding":"","journal":"Genomics & informatics","studyType":"Clinical Study"},{"pmid":"32462970","year":"2021","title":"Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.","finding":"","journal":"Journal of biomolecular structure & dynamics","studyType":"Clinical Study"},{"pmid":"31712208","year":"2020","title":"Second-Generation Antidiabetic Sulfonylureas Inhibit Candida albicans and Candidalysin-Mediated Activation of the NLRP3 Inflammasome.","finding":"","journal":"Antimicrobial agents and chemotherapy","studyType":"Clinical Study"},{"pmid":"29335817","year":"2018","title":"Repurposing existing drugs for new AMPK activators as a strategy to extend lifespan: a computer-aided drug discovery study.","finding":"","journal":"Biogerontology","studyType":"Clinical Study"}],"tags":[{"label":"glisoxepide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sulfonylurea receptor 1, Kir6.2","category":"target"},{"label":"ABCC8","category":"gene"},{"label":"KCNJ11","category":"gene"},{"label":"A10BB11","category":"atc"},{"label":"Active","category":"status"},{"label":"Diabetes mellitus type 2","category":"indication"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"glisepin","offLabel":[],"synonyms":["glisoxepide","glisepin","glisoxepid"],"timeline":[],"approvals":[],"brandName":"Glisepin","ecosystem":[{"indication":"Diabetes mellitus type 2","otherDrugs":[{"name":"acarbose","slug":"acarbose","company":"Bayer Hlthcare"},{"name":"acetohexamide","slug":"acetohexamide","company":"Lilly"},{"name":"albiglutide","slug":"albiglutide","company":"Glaxosmithkline Llc"},{"name":"alogliptin","slug":"alogliptin","company":"Takeda Pharms Usa"}],"globalPrevalence":537000000}],"mechanism":{"target":"Sulfonylurea receptor 1, Kir6.2","targets":[{"gene":"ABCC8","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-binding cassette sub-family C member 8"},{"gene":"KCNJ11","source":"DrugCentral","target":"Sulfonylurea receptor 1, Kir6.2","protein":"ATP-sensitive inward rectifier potassium channel 11"}],"modality":"Small Molecule","drugClass":"glisoxepide","explanation":"When you eat, your body breaks down the food into glucose, which is then released into your bloodstream. Normally, your pancreas releases insulin to help your cells absorb the glucose. Glisoxepide helps by keeping the potassium channels in your pancreas open, allowing more insulin to be released and helping your cells absorb the glucose more effectively.","oneSentence":"Glisoxepide works by blocking potassium channels in the pancreas, allowing more insulin to be released.","technicalDetail":"Glisoxepide acts as a selective antagonist of the sulfonylurea receptor 1 (SUR1), a regulatory subunit of the ATP-sensitive potassium channel (K_ATP) in pancreatic beta cells, thereby inhibiting the closure of K_ATP channels and increasing insulin secretion."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1305","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GLISOXEPIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GLISOXEPIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:45:42.320577","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:50:08.042199+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"glibenclamide","drugSlug":"glibenclamide","fdaApproval":"1984-05-01","relationship":"same-class"},{"drugName":"chlorpropamide","drugSlug":"chlorpropamide","fdaApproval":"1958-10-28","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolbutamide","drugSlug":"tolbutamide","fdaApproval":"1961-06-22","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tolazamide","drugSlug":"tolazamide","fdaApproval":"1966-07-18","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glipizide","drugSlug":"glipizide","fdaApproval":"1984-05-08","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glimepiride","drugSlug":"glimepiride","fdaApproval":"1995-11-30","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acetohexamide","drugSlug":"acetohexamide","fdaApproval":"1964-12-23","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"glisoxepide","indications":{"approved":[{"name":"Diabetes mellitus type 2","source":"DrugCentral","snomedId":44054006,"regulator":"FDA","usPrevalence":37300000,"globalPrevalence":537000000,"prevalenceMethod":"curated","prevalenceSource":"IDF Diabetes Atlas, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"glibenclamide","brandName":"glibenclamide","genericName":"glibenclamide","approvalYear":"1984","relationship":"same-class"},{"drugId":"chlorpropamide","brandName":"chlorpropamide","genericName":"chlorpropamide","approvalYear":"1958","relationship":"same-class"},{"drugId":"tolbutamide","brandName":"tolbutamide","genericName":"tolbutamide","approvalYear":"1961","relationship":"same-class"},{"drugId":"tolazamide","brandName":"tolazamide","genericName":"tolazamide","approvalYear":"1966","relationship":"same-class"},{"drugId":"glipizide","brandName":"glipizide","genericName":"glipizide","approvalYear":"1984","relationship":"same-class"},{"drugId":"glimepiride","brandName":"glimepiride","genericName":"glimepiride","approvalYear":"1995","relationship":"same-class"},{"drugId":"acetohexamide","brandName":"acetohexamide","genericName":"acetohexamide","approvalYear":"1964","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":1417914,"completionDate":"2015-04"},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":1499650,"completionDate":"2015-05"},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":["Diabetes Mellitus, Type 2"],"enrollment":886172,"completionDate":"2015-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006891","UNII":"H7SC0I332I","CHEBI":"CHEBI:135731","INN_ID":"2923","UMLSCUI":"C0061330","ChEMBL_ID":"CHEMBL2106618","KEGG_DRUG":"D07118","DRUGBANK_ID":"DB01289","PUBCHEM_CID":"32778","MESH_SUPPLEMENTAL_RECORD_UI":"C100171"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":43,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A10BB11","allCodes":["A10BB11"]},"biosimilarFilings":[],"recentPublications":[{"date":"2024 Sep 19","pmid":"39298002","title":"Deciphering the role of FOXP4 in long COVID: exploring genetic associations, evolutionary conservation, and drug identification through bioinformatics analysis.","journal":"Functional & integrative genomics"},{"date":"2023 Sep","pmid":"37813637","title":"M Protein from Dengue virus oligomerizes to pentameric channel protein: in silico analysis study.","journal":"Genomics & informatics"},{"date":"2021 Aug","pmid":"32462970","title":"Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.","journal":"Journal of biomolecular structure & dynamics"},{"date":"2020 Jan 27","pmid":"31712208","title":"Second-Generation Antidiabetic Sulfonylureas Inhibit Candida albicans and Candidalysin-Mediated Activation of the NLRP3 Inflammasome.","journal":"Antimicrobial agents and chemotherapy"},{"date":"2018 Apr","pmid":"29335817","title":"Repurposing existing drugs for new AMPK activators as a strategy to extend lifespan: a computer-aided drug discovery study.","journal":"Biogerontology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glisoxepide is a small molecule drug in the glisoxepide class that targets the sulfonylurea receptor 1, Kir6.2. It is used to treat diabetes mellitus type 2, but its commercial status and regulatory approval are unknown. As a sulfonylurea receptor 1 antagonist, glisoxepide works by inhibiting the closure of potassium channels in pancreatic beta cells, leading to increased insulin secretion. This mechanism helps to lower blood glucose levels in patients with type 2 diabetes. Further information on its pharmacokinetics and safety profile is not available.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:50:08.042199+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}